Alex De Caluwé

Tumour infiltrating lymphocytes and ductal carcinoma in situ: The art of thinking counterintuitively.

Auteurs : Salgado R, Fineberg S, De Caluwe A, de Azambuja E
Jaar : 2022
Journal : Eur J Cancer

Frailty in older adults with cancer (Fabio Gomez, editor) - Part III : Breast cancer in older adults with frailty

Auteurs : Dal Lago L, De Caluwe A, Borghgraef C, Dumont L, Pepersack T
Jaar : 2022
Journal : Book

Intraoperative electron radiotherapy in early invasive ductal breast cancer: 6-year median follow-up results of a prospective monocentric registry.

Auteurs : Philippson C, Larsen S, Simon S, Vandekerkhove C, De Caluwe A, Van Gestel D, Chintinne M, Veys I, De Neubourg F, Noterman D, Roman M, Nogaret JM, Desmet A
Jaar : 2022
Journal : Breast Cancer Res

Split-VMAT technique to control the deep inspiration breath hold time for breast cancer radiotherapy.

Auteurs : Poeta S, Jourani Y, De Caluwe A, Van den Begin R, Van Gestel D, Reynaert N
Jaar : 2021
Journal : Radiat Oncol

Neo-CheckRay: radiation therapy and adenosine pathway blockade to increase benefit of immuno-chemotherapy in early stage luminal B breast cancer, a randomized phase II trial.

Auteurs : De Caluwe A, Buisseret L, Poortmans P, Van Gestel D, Salgado R, Sotiriou C, Larsimont D, Paesmans M, Craciun L, Drisis S, Vandekerckhove C, Reyal F, Veys I, Eiger D, Piccart-Gebhart M, Romano E, Ignatiadis M
Jaar : 2021
Journal : BMC Cancer

Alex De Caluwé

Talen

Contact

Alex De Caluwé

Publicaties

Tumour infiltrating lymphocytes and ductal carcinoma in situ: The art of thinking counterintuitively.

Frailty in older adults with cancer (Fabio Gomez, editor) - Part III : Breast cancer in older adults with frailty

Intraoperative electron radiotherapy in early invasive ductal breast cancer: 6-year median follow-up results of a prospective monocentric registry.

Split-VMAT technique to control the deep inspiration breath hold time for breast cancer radiotherapy.

Neo-CheckRay: radiation therapy and adenosine pathway blockade to increase benefit of immuno-chemotherapy in early stage luminal B breast cancer, a randomized phase II trial.